Technology area: Biotechnology & Pharmaceuticals
14 pending office actions • 4 clients • 13 examiners • 11 art units • 0 of 14 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
K&L Gates - Novartis has 14 pending office actions in Biotechnology & Pharmaceuticals. The associated record lists 34332 career applications, a resolved allowance rate of 84.49%, and an average of 3.82 office actions per allowance. The profile combines a client-specific pending workload with the broader prosecution metrics supplied for the associated record.
The allowance rate and office-action average are historical measures and do not determine the result of a pending Novartis matter. They do provide context for planning responses in a field where claim scope may depend on molecular structure, biological activity, therapeutic use, or formulation. Practitioners should separate client-specific status from broader firm-level activity when assessing immediate deadlines and examination strategy.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (7%) |
| §112 only | 2 (14%) |
| Double-patenting only | 1 (7%) |
| Double-patenting + other | 3 (21%) |
| Multi-statute (no §101) | 7 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BENAVIDES, JENNIFER ANN | 2 | 50.8% | +47.3% |
| WEIDNER, ADAM M | 1 | 63.7% | +33.6% |
| REDDIG, PETER J | 1 | 58.0% | +40.2% |
| STAVROU, CONSTANTINA E | 1 | 42.4% | +35.6% |
| OUSPENSKI, ILIA I | 1 | 77.3% | +20.6% |
| SKELDING, ZACHARY S | 1 | 59.8% | +41.1% |
| HUYNH, PHUONG N | 1 | 65.8% | +53.6% |
| GROOMS, TIFFANY NICOLE | 1 | 57.8% | +46.3% |
| RAHMAN, MASUDUR | 1 | 72.9% | +31.7% |
| BATES, KEENAN ALEXANDER | 1 | 44.9% | +79.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16435257 | TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | BRISTOL, LYNN ANNE | 132d overdue |
| 16317943 | TREATMENT AND PREVENTION OF CYTOKINE RELEASE SYNDROME USING A CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH A KINASE INHIBITOR | LU, CHENG | 38d overdue |
| 18680465 | ANTIBODY MOLECULES TO PD-1 AND USES THEREOF | WEIDNER, ADAM M | — |
| 18420525 | TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY | REDDIG, PETER J | — |
| 18288345 | VIRAL VECTOR PRODUCTION SYSTEM | STAVROU, CONSTANTINA E | — |
| 18184860 | BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | SKELDING, ZACHARY S | — |
| 18009568 | ZBTB32 INHIBITORS AND USES THEREOF | RAHMAN, MASUDUR | — |
| 17602730 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | BATES, KEENAN ALEXANDER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18178886 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | HUYNH, PHUONG N | 15d overdue |
| 18680465 | ANTIBODY MOLECULES TO PD-1 AND USES THEREOF | WEIDNER, ADAM M | — |
| 18672871 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | BENAVIDES, JENNIFER ANN | — |
| 18420525 | TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY | REDDIG, PETER J | — |
| 18288345 | VIRAL VECTOR PRODUCTION SYSTEM | STAVROU, CONSTANTINA E | — |
| 18454457 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | BENAVIDES, JENNIFER ANN | — |
| 18326373 | METHODS FOR TREATING HEMATOLOGIC CANCERS | OUSPENSKI, ILIA I | — |
| 18184860 | BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | SKELDING, ZACHARY S | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Novartis | 6 |
| University of Pennsylvania | 6 |
| Harvard University | 1 |
| The Medical College of Wisconsin, Inc. | 1 |
| Art Unit | Apps |
|---|---|
| 1675 | 3 |
| 1644 | 2 |
| 1646 | 1 |
| 1632 | 1 |
| 1641 | 1 |
| 1637 | 1 |
| 1633 | 1 |
| 1631 | 1 |
| 1643 | 1 |
| 1642 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18680465 | ANTIBODY MOLECULES TO PD-1 AND USES THEREOF | President and Fellows of Harvard College | WEIDNER, ADAM M | 1675 | §101§103§112Other | Non-Final OA | — | Pending | May 31, 2024 |
| 18672871 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | Novartis AG | BENAVIDES, JENNIFER ANN | 1675 | §102§103§112DP | Non-Final OA | — | Pending | May 23, 2024 |
| 18420525 | TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY | The Trustees of the University of Pennsylvania | REDDIG, PETER J | 1646 | §102§103§112Other | Non-Final OA | — | Pending | Jan 23, 2024 |
| 18288345 | VIRAL VECTOR PRODUCTION SYSTEM | Novartis AG | STAVROU, CONSTANTINA E | 1632 | §102§103§112 | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18454457 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | Novartis AG | BENAVIDES, JENNIFER ANN | 1675 | §102§103§112DP | Non-Final OA | — | Pending | Aug 23, 2023 |
| 18326373 | METHODS FOR TREATING HEMATOLOGIC CANCERS | The Medical College of Wisconsin, Inc. | OUSPENSKI, ILIA I | 1644 | §112Other | Non-Final OA | — | Pending | May 31, 2023 |
| 18184860 | BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | Novartis AG | SKELDING, ZACHARY S | 1644 | §102§112Other | Non-Final OA | — | Pending | Mar 16, 2023 |
| 18178886 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | Novartis AG | HUYNH, PHUONG N | 1641 | §112Other | Non-Final OA | 15d overdue | Pending | Mar 06, 2023 |
| 18162236 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | The Trustees of the University of Pennsylvania | GROOMS, TIFFANY NICOLE | 1637 | §103§112DP | Final Rejection | — | Pending | Jan 31, 2023 |
| 18009568 | ZBTB32 INHIBITORS AND USES THEREOF | Novartis AG | RAHMAN, MASUDUR | 1633 | §102§103 | Final Rejection | — | Pending | Dec 09, 2022 |
| 17602730 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | The Trustees of the University of Pennsylvania | BATES, KEENAN ALEXANDER | 1631 | §102§103§112 | Non-Final OA | — | Pending | Oct 08, 2021 |
| 16435257 | TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | The Trustees of the University of Pennsylvania | BRISTOL, LYNN ANNE | 1643 | §103§112Other | Non-Final OA | 132d overdue | Pending | Jun 07, 2019 |
| 16317943 | TREATMENT AND PREVENTION OF CYTOKINE RELEASE SYNDROME USING A CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH A KINASE INHIBITOR | The Trustees of the University of Pennsylvania | LU, CHENG | 1642 | §103§112 | Non-Final OA | 38d overdue | Pending | Jan 15, 2019 |
| 16093758 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | The Trustees of the University of Pennsylvania | MARTINEZ, TARA L | 1654 | DP | Final Rejection | 16d overdue | Pending | Oct 15, 2018 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial84.5% of resolved applications prosecuted by K&L Gates - Novartis were allowed, across 34,332 applications in USPTO records.
3.82 office actions per allowed application on average.
14 pending office actions as of October 2026, for 4 clients, before 13 examiners in 11 art units.
